Insmed Inc.

(INSM) Trade

By |

Profile

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Contact Information

Website: www.insmed.com
Email: investor.relations@insmed.com
Main Phone: +1 908 977-9900
Address: 700 US Highway 202/206
Address 2: Building 202/206
State: NJ
City / Town: Bridgewater
Country: US
Postal Code: 08807

Issuer Information

Exchange: NGS
CEO: William Lewis
Employees: 435
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

Profile

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Contact Information

Website: www.insmed.com
Email: investor.relations@insmed.com
Main Phone: +1 908 977-9900
Address: 700 US Highway 202/206
Address 2: Building 202/206
State: NJ
City / Town: Bridgewater
Country: US
Postal Code: 08807

Issuer Information

Exchange: NGS
CEO: William Lewis
Employees: 435
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

$ 33.61 $ 0.15 (0.45%)
Last Price 33.61 Change $ 0.15 Change % 0.45 Tick N/A
Bid 29.00 Bid Size 1,000.00 Ask 36.90 Ask Size 100.00
Open 33.41 High 33.85 Low 32.93 Prev Close 33.46
Last Trade Volume 746,294 52 Wk Hi 35.32 52 Wk Low 12.10
Market Cap 3.4 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 101,480,980.00 EPS (TTM) -2.64 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 11 30
Number of Buys 9 19
Number of Sells 2 11
Net Activity 42462 90128
Last 10 Buys Shares
Christine A. Pellizzari 1,000
Christine A. Pellizzari 1,000
William Lewis 1,000
Melvin Sharoky 1,000
William Lewis 1,000
William Lewis 1,000
William Lewis 1,000
William Lewis 1,000
William Lewis 1,000
William Lewis 1,000
Last 10 Sell Shares
S. Nicole Schaeffer 1,000
S. Nicole Schaeffer 1,000
Donald J. Hayden 1,000
Donald J. Hayden 1,000
Melvin Sharoky 1,000
Melvin Sharoky 1,000
Donald J. Hayden 1,000
Donald J. Hayden 1,000
Melvin Sharoky 1,000
Melvin Sharoky 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 56 56 56 56
Low Target Price Estimate 35 35 35 35
Mean Target Price Estimate 41.67 41.67 41.71 41.67
Standard Deviation 7.53 7.53 6.87 7.53
Date of Most Recent Estimate 05/07/18 05/07/18 05/07/18 05/07/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 5 6 6 6
Moderate Buy 1 1 1 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.08 1.07 1.07 1